2023年脊柱关节炎(含银屑病关节炎)在研改善病情抗风湿药(DMARDs)管线:临床试验系统综述
该系统综述检索了17个国家和国际临床试验数据库(2023年2月),纳入已上市、在研或撤市的脊柱关节炎(SpA)DMARDs,按最先进临床开发阶段分析。中轴型SpA识别44种DMARDs(18种在研),银屑病关节炎识别44种(15种在研);结论认为治疗武器库将增强,但靶点多样性低,需发展策略或生物标志物辅助临床决策。
要点
- 中轴型SpA共识别44种DMARDs,其中18种在研(b+tsDMARDs),I期1项、II期10项、III期7项。
- 银屑病关节炎共识别44种DMARDs,其中15种在研,II期8项、III期7项。
- 中轴型SpA在研靶点以IL-17抑制剂(10种)为主,银屑病关节炎以JAK抑制剂(6种)和IL-17抑制剂(6种)为主。
核心结论
- 系统综述在中轴型SpA和银屑病关节炎分别识别18种和15种临床开发中的分子,提示未来数年治疗武器库将增强。
- DMARDs数量多但靶点多样性低,需要发展策略或生物标志物帮助临床医生做出知情治疗决策。
研究设计与样本
- 系统综述检索17个国家和国际临床试验数据库,检索时间为2023年2月,关键词为「spondyloarthritis」「ankylosing spondylitis」和「psoriatic arthritis」。
- 纳入已上市、临床开发中或已撤市的SpA所有DMARDs;每种分子仅考虑处于最先进临床开发阶段的研究。
主要发现
- 中轴型SpA共识别44种DMARDs:6种csDMARDs、27种bDMARDs和11种tsDMARDs。
- 中轴型SpA的18种在研靶向治疗(b+tsDMARDs)对应试验处于I期(n=1)、II期(n=10)和III期(n=7)。
- 中轴型SpA在研分子中10种为IL-17抑制剂、2种为Janus激酶(JAK)抑制剂、2种为粒细胞-巨噬细胞集落刺激因子抑制剂,4种为其他作用机制。
- 银屑病关节炎共识别44种DMARDs:5种csDMARDs、27种bDMARDs和12种tsDMARDs。
- 银屑病关节炎15种在研分子对应试验处于II期(n=8)和III期(n=7);6种为JAK抑制剂、6种为IL-17抑制剂、1种为IL-23抑制剂,2种为其他作用机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for spondyloarthritis (SpA) in the coming years. METHODS: We conducted a systematic review of 17 national and international clinical trial databases for all disease-modifying antirheumatic drugs (DMARDs) for SpA that are already marketed, in clinical development or withdrawn. The search was performed on February 2023 with the keywords "spondyloarthritis", "ankylosing spondylitis" and "psoriatic arthritis". For each molecule, we only considered the study at the most advanced stage of clinical development. RESULTS: Concerning axial SpA (axSpA), a total of 44 DMARDs were identified: 6 conventional synthetic DMARDs (csDMARDs), 27 biological DMARDs (bDMARDs) and 11 targeted synthetic DMARDs (tsDMARDs). Among the 18 targeted treatments (b+tsDMARDs) in current development, corresponding trials reached phase I (n=1), II (n=10) and III (n=7). Ten molecules are IL-17 inhibitors, two Janus kinase (JAK) inhibitors and two granulocyte-macrophage colony-stimulating factor inhibitors; four have another mode of action. Concerning psoriatic arthritis (PsA), 44 DMARDs were identified: 5 csDMARDs, 27 bDMARDs and 12 tsDMARDs. Among the 15 molecules in current development, corresponding trials reached phase II (n=8) and III (n=7). Six molecules are JAK inhibitors, six IL-17 inhibitors and one an IL-23 inhibitor; two have another mode of action. CONCLUSION: This systematic review identified 18 and 15 molecules in clinical development for axSpA and PsA, respectively, which suggests a strengthening of the therapeutic arsenal in the coming years. However, with so many DMARDs but low target diversity, we will need to develop strategies or biomarkers to help clinicians make informed treatment decisions.
引用
- Denis A, Sztejkowski C, Arnaud L, et al. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. 2023. PMID: 37507210. doi:10.1136/rmdopen-2023-003279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。